Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Int J Tuberc Lung Dis ; 27(8): 619-625, 2023 08 01.
Article in English | MEDLINE | ID: mdl-37491747

ABSTRACT

BACKGROUND: P1041 was a randomised, placebo-controlled isoniazid prophylaxis trial in South Africa. We studied predictors for TB in HIV-exposed children participating in the P1041 trial.METHODS: We included data from entry until Week 108. Predictors considered were type of housing, overcrowding, age, sex, ethnicity, tobacco exposure, weight-for-age percentile Z-score (WAZ), CD4%, viral load (VL), antiretroviral therapy (ART) and number of household smokers.RESULTS: Of 543 HIV-positive (HIV+) and 808 HIV-exposed uninfected (HEU) infants at entry, median age was 96 days (interquartile range: 92-105). Of 1,351 caregivers, 125 (9%) had a smoking history, and 62/1,351 reported current smoking. In 594/1,351 (44%) households, there was at least one smoker. Smoking caregivers consumed 1-5 cigarettes daily. In the HIV+ cohort, significant baseline TB predictors after adjusting covariates were as follows: WAZ (adjusted hazard ratio [aHR] 0.76, P = 0.002) and log10 HIV RNA copies/ml (aHR 1.50, P = 0.009). Higher CD4% (aHR 0.88, P = 0.002) and ART (aHR 0.50, P = 0.006) were protective. In the HEU cohort, smoking exposure was associated with reduced TB-free survival on univariate analysis, but not after adjustment in the multivariate model.CONCLUSION: Low WAZ and high VL were strong predictors of TB disease or death. Rising CD4 percentage and being on ART were protective in the HIV+ cohort.


Subject(s)
HIV Infections , Tuberculosis , Infant , Humans , Child , Tuberculosis/epidemiology , HIV Infections/drug therapy , HIV Infections/epidemiology , Africa, Southern , South Africa/epidemiology , Isoniazid/therapeutic use
2.
Int J Tuberc Lung Dis ; 22(5): 34-39, 2018 05 01.
Article in English | MEDLINE | ID: mdl-29665951

ABSTRACT

The inclusion of newly licensed or repurposed drugs in regimens to treat children for multidrug-resistant tuberculosis (TB) may lead to treatment that is shorter than traditional regimens and composed only of oral medications. As an all-oral regimen may be more acceptable and have a better safety profile than current regimens, demonstrating non-inferiority may be satisfactory. Demonstrating non-inferior efficacy requires setting a non-inferiority margin and safeguarding study assay sensitivity. Multi-arm, multistage designs may currently not be appropriate in pediatric trials because of the lack of sensitive and specific intermediate outcomes. However, including an arm with an agent to ameliorate toxicity would be efficient. Covariates can be used to stratify randomization, define subgroups, and improve efficiency of analysis. Enriching the sample for the confirmed-TB subgroup to ensure that they are well represented may be important. Primary outcomes using a fixed timepoint from randomization for all study arms will result in variations in post-treatment duration, but may be the best choice. While blinding of site personnel and patients may not be possible when regimens differ substantially in drugs and modes of administration, blinding should be maintained for independent endpoint review groups and other personnel. Type I error and family-wise error rates should be tightly controlled.


Subject(s)
Antitubercular Agents/therapeutic use , Randomized Controlled Trials as Topic/methods , Tuberculosis, Multidrug-Resistant/drug therapy , Child , Data Interpretation, Statistical , Humans , Research Design
3.
Int J Tuberc Lung Dis ; 20(8): 1060-4, 2016 08.
Article in English | MEDLINE | ID: mdl-27393540

ABSTRACT

BACKGROUND: Identifying source cases of children exposed to tuberculosis (TB) is challenging. We examined the time-point of obtaining contact information of TB source cases in human immunodeficiency virus (HIV) infected and HIV-exposed uninfected (HEU) children in a randomised, placebo-controlled trial of pre-exposure to isoniazid prophylaxis. METHODS: A total of 543 HIV-infected and 808 HEU infants without TB exposure aged 3-4 months were enrolled between 2004 and 2008. At 3-monthly follow-up, infants were evaluated for TB and care givers were asked about new TB exposure. RESULTS: In total, 128 cases of TB disease and 40 deaths were recorded among 19% (105/543) of the HIV-infected and 8% (63/808) of the HEU children; 229 TB contact occasions were reported in 205/1351 (15%) children, of which 83% (189/229) were in the household. Of the 189 household contacts, 108 (53%) underwent microbiological evaluations; 81% (87/108) were positive. HIV-infected and HEU infants had similar frequencies of TB contact: in 48% of infants with definite TB, 58% with probable TB and 43% with possible TB. Of 128 children diagnosed with TB, a TB contact was identified for 59. Of these, 29/59 (49%) were identified at or after the child's TB diagnosis. CONCLUSION: TB source cases are often identified at or after a child's TB diagnosis. More effort is required for earlier detection.


Subject(s)
Antitubercular Agents/administration & dosage , Coinfection , HIV Infections/epidemiology , Isoniazid/administration & dosage , Primary Prevention , Tuberculosis, Pulmonary/prevention & control , Age Factors , Antitubercular Agents/adverse effects , Early Diagnosis , Female , HIV Infections/diagnosis , HIV Infections/mortality , Humans , Infant , Isoniazid/adverse effects , Male , Prevalence , Risk Factors , South Africa , Time Factors , Treatment Outcome , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/mortality , Tuberculosis, Pulmonary/transmission
SELECTION OF CITATIONS
SEARCH DETAIL
...